Heparin and related polysaccharides: synthesis using recombinant enzymes and metabolic engineering

Applied Microbiology and Biotechnology

Volumn 99, Issue 18, 2015, Pages 7465-7479

  Suflita, Matthew ^a   Fu, Li ^b   He, Wenqin ^b   Koffas, Mattheos ^a,b   Linhardt, Robert J ^a,b  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Chemoenzymatic; Chondroitin sulfate; Glycosaminoglycans; Glycosyltransferases; Heparin; Metabolic engineering; PAPS; Recombinant enzymes; Sulfotransferases

Indexed keywords

ANIMALS; BIOCHEMICAL ENGINEERING; ENZYMES; HISTOLOGY; HYDROGELS; IMPURITIES; METABOLISM; POLYSACCHARIDES; SULFUR COMPOUNDS; TISSUE;

CHEMOENZYMATIC; CHONDROITIN SULFATES; GLYCOSAMINOGLYCANS; GLYCOSYLTRANSFERASES; HEPARIN; PAPS; RECOMBINANT ENZYMES; SULFOTRANSFERASES;

METABOLIC ENGINEERING;

2 O SULFOTRANSFERASE 1; 3 O SULFOTRANSFERASE 1; 6 O SULFOTRANSFERASE 1; 6 O SULFOTRANSFERASE 3; ARDEPARIN; CERTROPARIN SODIUM; CHONDROITIN; CHONDROITIN POLYMERASE; CHONDROITIN SULFATE; CHONDROITIN SYNTHASE; DALTEPARIN; DERMATAN SULFATE; ENOXAPARIN; EPIMERASE; FONDAPARINUX; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN POLYSULFATE; GLYCOSYLTRANSFERASE; HEPARIN; HEPAROSAN SYNTHASE 1; HEPAROSAN SYNTHASE 2; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OLIGOSACCHARIDE; POLYSACCHARIDE; RECOMBINANT ENZYME; REVIPARIN; SEMULOPARIN; SULFOTRANSFERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; RECOMBINANT PROTEIN;

BIOENGINEERING; BIOLOGICAL PRODUCTION; BIOTECHNOLOGY; ENZYME ACTIVITY; METABOLISM; PHARMACEUTICAL INDUSTRY; POLYSACCHARIDE; RECOMBINATION; SULFATE;

BIOTECHNOLOGICAL PRODUCTION; CARBOHYDRATE SYNTHESIS; CHEMICAL STRUCTURE; CHO CELL LINE; DEPOLYMERIZATION; DNA MODIFICATION; ENZYME ACTIVITY; ENZYME ENGINEERING; EPIMERIZATION; FED BATCH FERMENTATION; FERMENTATION OPTIMIZATION; GENE CLUSTER; GENE DOSAGE; GENE EXPRESSION; GLYCOSYLATION; HUMAN; METABOLIC ENGINEERING; MOLECULAR WEIGHT; NONHUMAN; PROMOTER REGION; REVIEW; STEREOCHEMISTRY; TRANSPOSON; BIOSYNTHESIS; BIOTECHNOLOGY; GENETICS; METABOLISM; PROCEDURES;

ANIMALIA;

BIOTECHNOLOGY; GLYCOSAMINOGLYCANS; GLYCOSYLTRANSFERASES; METABOLIC ENGINEERING; RECOMBINANT PROTEINS; SULFOTRANSFERASES;

EID: 84939564232     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-015-6821-9     Document Type: Review

References (120)

1. Adebowale AO, Cox DS, Liang Z, Eddington ND (2000) Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. J Am Nutraceutical Assoc 3:37–44
2. Baik JY, Gasimli L, Yang B, Datta P, Zhang F, Glass CA, Esko JD, Linhardt RJ, Sharfstein ST (2012) Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin. Metab Eng 14:81–90. doi:10.1016/j.ymben.2012.01.008
3. Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729–777. doi:10.1146/annurev.biochem.68.1.729
4. Berninsone P, Hirschberg C (1998) Heparan sulfate/heparin N-deacetylase/N-sulfotransferase: the N-sulfotransferase activity domain is at the carboxyl half of the holoenzyme. J Biochem 273:25556–25559
5. Bhan N, Xu P, Koffas MAG (2013) Pathway and protein engineering approaches to produce novel and commodity small molecules. Curr Opin Biotechnol 24:1137–1143. doi:10.1016/j.copbio.2013.02.019
6. Bhaskar U, Sterner E, Hickey AM, Onishi A, Zhang F, Dordick JS, Linhardt RJ (2012) Engineering of routes to heparin and related polysaccharides. Appl Microbiol Biotechnol 93:1–16. doi:10.1007/s00253-011-3641-4
7. Bhaskar U, Li G, Fu L, Onishi A, Suflita M, Dordick J, Linhardt RJ (2015) Combinatorial one-pot chemoenzymatic synthesis of heparin. Carbohydr Polymer 122:399–407
8. Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA (2005) Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am 19:1–51. doi:10.1016/j.hoc.2004.09.003
9. Burkart M, Wong C (1999) A continuous assay for the spectrophotometric analysis of sulfotransferases using aryl sulfotransferase IV. Anal Biochem 274:131–137. doi:10.1006/abio.1999.4264
10. Burkart M, Izumi M, Chapman E, Lin C, Wong C (2000) Regeneration of PAPS for the enzymatic synthesis of sulfated oligosaccharides. J Org Chem 65:5565–5574
11. Castelli R, Porro F, Tarsia P (2004) The heparins and cancer: review of clinical trials and biological properties. Vasc Med 9:205–213. doi:10.1191/1358863x04vm566ra
12. Chavaroche AAE, Van Den Broek LAM, Boeriu C, Eggink G (2012) Synthesis of heparosan oligosaccharides by Pasteurella multocida PmHS2 single-action transferases. Appl Microbiol Biotechnol 95:1199–1210. doi:10.1007/s00253-011-3813-2
13. Chen M, Bridges A, Liu J (2006) Determination of the substrate specificities of N-acetyl-d-glucosaminyltransferase. Biochemistry 45:12358–12365
14. Chen Y, Li Y, Yu H, Sugiarto G, Thon V, Hwang J, Ding L, Hie L, Chen X (2013) Tailored design and synthesis of heparan sulfate oligosaccharide analogues using sequential one-pot multienzyme systems. Angew Chem Int Ed Engl 52:11852–11856. doi:10.1002/anie.201305667
15. Cimini D, Restaino OF, Catapano A, De Rosa M, Schiraldi C (2010a) Production of capsular polysaccharide from Escherichia coli K4 for biotechnological applications. Appl Microbiol Biotechnol 85:1779–1787. doi:10.1007/s00253-009-2261-8
16. Cimini D, De Rosa M, Viggiani A, Restaino OF, Carlino E, Schiraldi C (2010b) Improved fructosylated chondroitin production by kfoC overexpression in E. coli K4. J Biotechnol 150:324–331. doi:10.1016/j.jbiotec.2010.09.954
17. Cimini D, De Rosa M, Carlino E, Ruggiero A, Schiraldi C (2013) Homologous overexpression of rfaH in E. coli K4 improves the production of chondroitin-like capsular polysaccharide. Microb Cell Factories 12:46. doi:10.1186/1475-2859-12-46
18. Clarke BR, Esumeh F, Roberts IS (2000) Cloning, expression, and purification of the K5 capsular polysaccharide lyase (KflA) from coliphage K5A: evidence for two distinct K5 lyase enzymes. J Bacteriol 182:3761–3766
19. Cress BF, Englaender JA, He W, Kasper D, Linhardt RJ, Koffas MAG (2014) Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules. FEMS Microbiol Rev 38:660–697. doi:10.1111/1574-6976.12056
20. Cress BF, Toparlak OD, Guleria S, Lebovich M, Stieglitz JT, Englaender JA, Jones JA, Linhardt RJ, Koffas MAG (2015) CRISPathBrick: modular combinatorial assembly of type II-A CRISPR arrays for dCas9-mediated multiplex transcriptional repression in E. coli. ACS Synth Biol. doi:10.1021/acssynbio.5b00012
21. Datta P, Li G, Yang B, Zhao X, Baik JY, Gemmill TR, Sharfstein ST, Linhardt RJ (2013a) Bioengineered Chinese hamster ovary cells with Golgi-targeted 3-O-sulfotransferase-1 biosynthesize heparan sulfate with an antithrombin-binding site. J Biol Chem 288:37308–37318. doi:10.1074/jbc.M113.519033
22. Datta P, Linhardt RJ, Sharfstein ST (2013b) An ’omics approach towards CHO cell engineering. Biotechnol Bioeng 110:1255–1271. doi:10.1002/bit.24841
23. DeAngelis PL, White CL (2002) Identification and molecular cloning of a heparosan synthase from Pasteurella multocida type D. J Biol Chem 277:7209–7213. doi:10.1074/jbc.M112130200
24. Deangelis PL, Liu J, Linhardt RJ (2013) Chemoenzymatic synthesis of glycosaminoglycans: re-creating, re-modeling and re-designing nature’s longest or most complex carbohydrate chains. Glycobiology 23:764–777. doi:10.1093/glycob/cwt016
25. Doherty DH, Weaver CA, Miyamoto K, Minamisawa T (2011) Compositions and methods for bacterial production of chondroitin. US Patent# US20110244520 A1
26. Esko JD, Lindahl U (2001) Molecular diversity of heparan sulfate. J Clin Invest 108:169–173. doi:10.1172/JCI13530
27. Esko JD, Selleck SB (2002) Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71:435–471. doi:10.1146/annurev.biochem.71.110601.135458
28. Evans TD, Mozen MM (1962) Process for purifying heparin. US Patent #3058884
29. Fu L, Li G, Yang B, Onishi A, Li L, Sun P, Zhang F, Linhardt R (2013) Structural characterization of pharmaceutical heparins prepared from different animal tissues. J Pharm Sci 102:1447–1457
30. Fu L, Li L, Cai C, Li G, Zhang F, Linhardt RJ (2014a) Heparin stability by determining unsubstituted amino groups using hydrophilic interaction chromatography mass spectrometry. Anal Biochem 461:46–48. doi:10.1016/j.ab.2014.05.028
31. Fu L, Zhang F, Li G, Onishi A, Bhaskar U, Sun P, Linhardt RJ (2014b) Structure and activity of a new low-molecular-weight heparin produced by enzymatic ultrafiltration. J Pharm Sci 10(100):1375–1383. doi:10.1002/jps.23939
32. Gijsen HJM, Qiao L, Fitz W, Wong C-H (1996) Recent advances in the chemoenzymatic synthesis of carbohydrates and carbohydrate mimetics. Chem Rev 96:443–474. doi:10.1021/cr950031q
33. Griffiths G, Barrett B, Cook N, Roberts IS (1999) Biosynthesis of the Escherichia coli K5 capsular polysaccharide. Biochem Soc Trans 27:507–512
34. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R (2008) Oversulfated chondroitin sulfate is a major contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:669–675
35. He W, Fu L, Li G, Jones A, Linhardt RJ, Koffas M (2015) Production of chondroitin in metabolically engineered E. coli. Metab Eng 27:92–100. doi:10.1016/j.ymben.2014.11.003
36. Higashi K, Hosoyama S, Ohno A, Masuko S, Yang B, Sterner E, Wang Z, Linhardt R, Toida T (2012) Photochemical preparation of a novel molecular weight heparin. Carbohydr Polym 87:1737–1743
37. Higashi K, Takeuchi Y, Mukuno A, Tomitori H, Miya M, Linhardt RJ, Toida T (2015) Composition of glycosaminoglycans in elasmobranchs including several deep-sea sharks: identification of chondroitin/dermatan sulfate from the dried fins of Isurus oxyrinchus and Prionace glauca. PLoS One 10, e0120860. doi:10.1371/journal.pone.0120860
38. Jones JA, Toparlak ÖD, Koffas MA (2015) Metabolic pathway balancing and its role in the production of biofuels and chemicals. Curr Opin Biotechnol 33:52–59. doi:10.1016/j.copbio.2014.11.013
39. Karst NA, Linhardt RJ (2003) Recent chemical and enzymatic approaches to the synthesis of glycosaminoglycan oligosaccharides | BenthamScience. Curr Med Chem 10:1993–2031
40. Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE (1994) Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269:18881–18890
41. Keire DA, Buhse LF, Al-Hakim A (2013) Characterization of currently marketed heparin products: composition analysis by 2D-NMR. Anal Methods 5:2984–2994
42. Kuberan B, Lech MZ, Beeler DL, Wu ZL, Rosenberg RD (2003) Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat Biotechnol 21:1343–1346. doi:10.1038/nbt885
43. Kusche-Gullberg M, Kjellén L (2003) Sulfotransferases in glycosaminoglycan biosynthesis. Curr Opin Struct Biol 13:605–611. doi:10.1016/j.sbi.2003.08.002
44. Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG (2009) AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery—TREK: a dose-ranging study. J Thromb Haemost 7:566–572. doi:10.1111/j.1538-7836.2009.03301.x
45. Lauder RM (2009) Chondroitin sulphate: a complex molecule with potential impacts on a wide range of biological systems. Complement Ther Med 17:56–62. doi:10.1016/j.ctim.2008.08.004
46. Li JP, Vlodavsky I (2009) Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 102:823–828. doi:10.1160/TH09-02-0091
47. Li L, Zhang F, Zaia J, Linhardt RJ (2012) Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS. Anal Chem 84:8822–8829. doi:10.1021/ac302232c
48. Li G, Li L, Tian F, Zhang L, Xue C, Linhardt RJ (2015) Glycosaminoglycanomics of cultured cells using a rapid and sensitive LC-MS/MS approach. ACS Chem Biol. doi:10.1021/acschembio.5b00011
49. Lindahl U, Kusche-Gullberg M, Kjellen L (1998) Regulated diversity of heparan sulfate. J Biol Chem 273:24979–24982. doi:10.1074/jbc.273.39.24979
50. Lindahl U, Li J, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa T, Emeis J, Roberts I, Taylor C, Oreste P, Zopetti G, Naggi A, Torri G, Casu B (2005) Generation of “neoheparin” from E. coli K5 capsular polysaccharide. J Med Chem 48(2):349--352. doi:10.1021/jm049812m
51. Linhardt RJ (2003) Heparin: strucuture and activity. J Med Chem 46:2521–2564
52. Linhardt RJ, Liu J (2012) Synthetic heparin. Curr Opin Pharmacol 12:217–219. doi:10.1016/j.coph.2011.12.002
53. Linhardt RJ, Ampofo SA, Fareed J, Hoppensteadt D, Folkman J, Mulliken JB (1992) Isolation and characterization of human heparin. Biochemistry 31:12441–12445. doi:10.1021/bi00164a020
54. Liu J, Shriver Z, Pope RM, Thorp SC, Duncan MB, Copeland RJ, Raska CS, Yoshida K, Eisenberg RJ, Cohen G, Linhardt RJ, Sasisekharan R (2002) Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem 277:33456–33467. doi:10.1074/jbc.M202034200
55. Liu H, Zhang Z, Linhardt RJ (2009) Lessons learned from the contamination of heparin. Nat Prod Rep 26:313–321. doi:10.1039/b819896a
56. Liu R, Xu Y, Chen M, Weïwer M, Zhou X, Bridges AS, DeAngelis PL, Zhang Q, Linhardt RJ, Liu J (2010) Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem 285:34240–34249. doi:10.1074/jbc.M110.159152
57. Liu C, Sheng J, Krahn JM, Perera L, Xu Y, Hsieh PH, Dou W, Liu J, Pedersen LC (2014) Molecular mechanism of substrate specificity for heparan sulfate 2-O-sulfotransferase. J Biol Chem 289:13407–13418. doi:10.1074/jbc.M113.530535
58. Loganathan D, Wang HM, Mallis LM, Linhardt RJ (1990) Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry 29:4362–4368
59. Manzoni M, Bergomi S, Molinari F, Cavazzoni V (1996) production and purification of an extracellularly produced K4 polysaccharide from Escherichia coli. Biotechnol Lett 4:383–386. doi:10.1007/BF00143456
60. Masuko S, Bera S, Green DE, Weïwer M, Liu J, Deangelis PL, Linhardt RJ (2012) Chemoenzymatic synthesis of uridine diphosphate-GlcNAc and uridine diphosphate-GalNAc analogs for the preparation of unnatural glycosaminoglycans. J Org Chem 77:1449–1456. doi:10.1021/jo202322k
61. Mikami T, Kitagawa H (2013) Biosynthesis and function of chondroitin sulfate. Biochim Biophys Acta Gen Subj 1830:4719–4733. doi:10.1016/j.bbagen.2013.06.006
62. Moon AF, Edavettal SC, Krahn JM, Munoz EM, Negishi M, Linhardt RJ, Liu J, Pedersen LC (2004) Structural analysis of the sulfotransferase (3-O-sulfotransferase isoform 3) involved in the biosynthesis of an entry receptor for herpes simplex virus 1. J Biol Chem 279:45185–45193. doi:10.1074/jbc.M405013200
63. Moon AF, Xu Y, Woody SM, Krahn JM, Linhardt RJ, Liu J, Pedersen LC (2012) Dissecting the substrate recognition of 3-O-sulfotransferase for the biosynthesis of anticoagulant heparin. Proc Natl Acad Sci 109:5265–5270. doi:10.1073/pnas.1117923109
64. Mousa SA, Fareed J (2001) Overview: from heparin to low molecular weight heparin: beyond anticoagulation. Curr Opin Investig Drugs 2:1077–1080
65. Murugesan S, Xie J, Linhardt RJ (2008) Immobilization of heparin: approaches and applications. Curr Top Med Chem 8:80–100. doi:10.2174/156802608783378891
66. Naggi A, Torri G, Casu B, Oreste P, Zoppetti G, Li JP, Lindahl U (2001) Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide. Semin Thromb Hemost 27:437–443. doi:10.1055/s-2001-17954
67. Okuyama T, Yoshida K, Sakuraik, Ogurat, Horie K, Tawada A (1975) Method of separating and recovering mucopolysaccharides from connective tissues of animals. US Patent #3862003
68. Orellana A, Hirschberg CB, Wei Z, Swiedler SJ, Ishihara M (1994) Molecular cloning and expression of a glycosaminoglycan N-acetylglucosaminyl N-deacetylase/N-sulfotransferase from a heparin-producing cell line. J Biol Chem 269:2270–2276
69. Osterman MT, Lichtenstein GR (2007) Current and future anti-TNF therapy for inflammatory bowel disease. Curr Treat Options in Gastroenterol 10:195–207. doi:10.1007/s11938-007-0013-3
70. Pacheco B, Maccarana M, Goodlett DR, Malmström A, Malmström L (2009a) Identification of the active site of DS-epimerase 1 and requirement of N-glycosylation for enzyme function. J Biol Chem 284:1741–1747. doi:10.1074/jbc.M805479200
71. Pacheco B, Malmström A, Maccarana M (2009b) Two dermatan sulfate epimerases form iduronic acid domains in dermatan sulfate. J Biol Chem 284:9788–9795. doi:10.1074/jbc.M809339200
72. Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A (2013) Infliximab in psoriasis and psoriatic arthritis. BioDrugs 27(Suppl 1):13–23. doi:10.1007/BF03325638
73. Parish CR, Freeman C, Hulett MD (2001) Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471:M99–M108
74. Petitou M, Duchaussoy P, Lederman I, Choay J, Sinaÿ P, Jacquinet J-C, Torri G (1986) Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-D-glucopyranosyl)-(1–4)-O-(beta-D-glucopyranosyluronic acid)-(1–4)-O-(2-O-sulfo-alpha-L-idopyranosyluronic acid)-(1–4)-2-deoxy-2-sulfamido-6-. Carbohydr Res 147:221–236
75. Qin Y, Ke J, Gu X, Fang J, Wang W, Cong Q, Li J, Tan J, Brunzelle JS, Zhang C, Jiang Y, Melcher K, Li J, Xu HE, Ding K (2015) Structural and functional study of D-glucuronyl C5-epimerase. J Biol Chem 290:4620–4630. doi:10.1074/jbc.M114.602201
76. Ramani VC, Purushothaman A, Stewart M, Thompson C, Vlodavsky I, Au J, Sanderson RD (2013) The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J 280:2294–2306. doi:10.1016/j.biotechadv.2011.08.021
77. Restaino OF, Cimini D, De Rosa M, Catapano A, Schiraldi C, De Rosa M, Catapano A, Schiraldi C, De Rosa M, Catapano A, Schiraldi C (2011) High cell density cultivation of Escherichia coli K4 in a microfiltration bioreactor: a step towards improvement of chondroitin precursor production. Microb Cell Factories 10:1–11. doi:10.1186/1475-2859-10-10
78. Restaino OF, Bhaskar U, Paul P, Li L, De Rosa M, Dordick JS, Linhardt RJ (2013a) High cell density cultivation of a recombinant E. coli strain expressing a key enzyme in bioengineered heparin production. Appl Microbiol Biotechnol 97:3893–3900. doi:10.1007/s00253-012-4682-z
79. Restaino OF, di Lauro I, Cimini D, Carlino E, De Rosa M, Schiraldi C (2013b) Monosaccharide precursors for boosting chondroitin-like capsular polysaccharide production. Appl Microbiol Biotechnol 97:1699–1709. doi:10.1007/s00253-012-4343-2
80. Sakai S, Otake E, Toida T, Goda Y (2007) Identification of the origin of chondroitin sulfate in “health foods”. Chem Pharm Bull (Tokyo) 55:299–303
81. Saribaş AS, Mobasseri A, Pristatsky P, Chen X, Barthelson R, Hakes D, Wang J (2004) Production of N-sulfated polysaccharides using yeast-expressed N-deacetylase/N-sulfotransferase-1 (NDST-1). Glycobiology 14:1217–1228. doi:10.1093/glycob/cwh129
82. Sasisekharan R, Venkataraman G (2000) Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 4:626–631. doi:10.1016/S1367-5931(00)00145-9
83. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH (2004) Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10:55–63. doi:10.1038/nm979
84. Schiraldi C, Cimini D, De Rosa M (2010) Production of chondroitin sulfate and chondroitin. Appl Microbiol Biotechnol 87:1209–1220. doi:10.1007/s00253-010-2677-1
85. Schonberger L (1998) New variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Infect Dis Clin N Am 12:111–121
86. Sheng J, Liu R, Xu Y, Liu J (2011) The dominating role of N-deacetylase/N-sulfotransferase 1 in forming domain structures in heparan sulfate. J Biol Chem 286:19768–19776. doi:10.1074/jbc.M111.224311
87. Sheng J, Xu Y, Dulaney SB, Huang X, Liu J (2012) Uncovering biphasic catalytic mode of C5-epimerase in heparan sulfate biosynthesis. J Biol Chem 287:20996–21002. doi:10.1074/jbc.M112.359885
88. Shi X, Zaia J (2009) Organ-specific heparan sulfate structural phenotypes. J Biol Chem 284:11806–11814. doi:10.1074/jbc.M809637200
89. Silbert JE, Sugumaran G (2002) Biosynthesis of chondroitin/dermatan sulfate. IUBMB Life 54:177–186. doi:10.1080/15216540290114450
90. Sismey-Ragatz AE, Green DE, Otto NJ, Rejzek M, Field RA, DeAngelis PL (2007) Chemoenzymatic synthesis with distinct Pasteurella heparosan synthases: monodisperse polymers and unnatural structures. J Biol Chem 282:28321–28327. doi:10.1074/jbc.M701599200
91. Sterner E, Li L, Paul P, Beaudet JM, Liu J, Linhardt RJ, Dordick JS (2014) Assays for determining heparan sulfate and heparin O-sulfotransferase activity and specificity. Anal Bioanal Chem 406:525–536. doi:10.1007/s00216-013-7470-4
92. Sugiura N, Tawada A, Sugimoto K, Watanabe H (2002) Molecular cloning and characterization of chondroitin polymerase from Escherichia coli strain K4. J Biol Chem 277:21567–21575. doi:10.1074/jbc.M201719200
93. Sugiura N, Shioiri T, Chiba M, Sato T, Narimatsu H, Kimata K, Watanabe H (2012) Construction of a chondroitin sulfate library with defined structures and analysis of molecular interactions. J Biol Chem 287:43390–43400. doi:10.1074/jbc.M112.412676
94. Sun X, Li L, Overdier KH, Ammons LA, Douglas IS, Burlew CC, Zhang F, Schmidt EP, Chi L, Linhardt RJ (2015) Analysis of total human urinary glycosaminoglycan disaccharides by liquid chromatography–tandem mass spectrometry. Anal Chem 87:6220–6227. doi:10.1021/acs.analchem.5b00913
95. Taipale J, Keski-Oja J (1997) Growth factors in the extracellular matrix. FASEB J Off Publ Fed Am Soc Exp Biol 11:51–59
96. Thelin MA, Bartolini B, Axelsson J, Gustafsson R, Tykesson E, Pera E, Oldberg A, MacCarana M, Malmstrom A (2013) Biological functions of iduronic acid in chondroitin/dermatan sulfate. FEBS J 280:2431–2446. doi:10.1111/febs.12214
97. Toschi V, Lettino M (2007) Fondaparinux: pharmacology and clinical experience in cardiovascular medicine. Mini - Rev Med Chem 7:383–387
98. Tully SE, Rawat M, Hsieh-Wilson LC (2006) Discovery of a TNF-alpha antagonist using chondroitin sulfate microarrays. J Am Chem Soc 128:7740–7741. doi:10.1021/ja061906t
99. Van Gorp CL, Vosburgh F, Schubert RL (1997) Protein hydrolysate derived from mucosa tissue. US Patent #5607840
100. Vidic H-J (1981) Process for the preparation of heparin. US Patent # 4283530.
101. Viskov C, Just M, Laux V, Mourier P, Lorenz M (2009) Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost 7:1143–1151. doi:10.1111/j.1538-7836.2009.03447.x
102. Vlodavsky I, Friedmann Y (2001) Heparan sulfate proteoglycans molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Investig 108:341–347. doi:10.1172/JCI200113662
103. Wang Z, Yang B, Zhang Z, Mellisa L, Takieddin M, Mousa S, Liu J, Dordick JS, Linhardt RJ (2011) Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Appl Microbiol Biotechnol 91:91–99
104. Wang W, Englaender JA, Xu P, Mehta KK, Suwan J, Dordick JS, Zhang F, Yuan Q, Linhardt RJ, Koffas M (2013) Expression of low endotoxin 3-o-sulfotransferase in Bacillus subtilis and Bacillus megaterium. Appl Biochem Biotechnol 171:954–962. doi:10.1007/s12010-013-0415-8
105. Williams RE (1967) Process for the recovery of heparin. US Patent #3337409
106. Wu Q, Yang A, Zou W, Duan Z, Liu J, Chen J, Liu L (2013) Transcriptional engineering of Escherichia coli K4 for fructosylated chondroitin production. Biotechnol Prog 29:1140–1149. doi:10.1002/btpr.1777
107. Xiong J, Bhaskar U, Li G, Fu L, Li L, Zhang F, Dordick JS, Linhardt RJ (2013) Immobilized enzymes to convert N-sulfo, N-acetyl heparosan to a critical intermediate in the production of bioengineered heparin. J Biotechnol 167:241–247. doi:10.1016/j.jbiotec.2013.06.018
108. Xu Y, Masuko S, Takieddin M, Xu H, Liu R, Jing J, Mousa SA, Linhardt RJ, Liu J, Xu Y, Masuko S, Takieddin M, Xu H, Liu R, Jing J, Mousa S, Linhardt RJ, Liu J (2011) Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins. Science 334(80-):498–501. doi:10.1126/science.1207478
109. Xu P, Bhan N, Koffas MAG (2013) Engineering plant metabolism into microbes: from systems biology to synthetic biology. Curr Opin Biotechnol 24:291–299. doi:10.1016/j.copbio.2012.08.010
110. Xu Y, Cai C, Chandarajoti K, Hsieh P-H, Li L, Pham TQ, Sparkenbaugh EM, Sheng J, Key NS, Pawlinski R, Harris EN, Linhardt RJ, Liu J (2014) Homogenous low-molecular-weight heparins with reversible anticoagulant activity. Nat Chem Biol 10:248–250. doi:10.1038/nchembio.1459
111. Yang B, Chang Y, Weyers AM, Sterner E, Linhardt RJ (2012) Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography-mass spectrometry. J Chromatogr A 1225:91–98. doi:10.1016/j.chroma.2011.12.063
112. Zanfardino A, Restaino OF, Notomista E, Cimini D, Schiraldi C, De Rosa M, De Felice M, Varcamonti M (2010) Isolation of an Escherichia coli K4 kfoC mutant over-producing capsular chondroitin. Microb Cell Factories 9:34. doi:10.1186/1475-2859-9-34
113. Zhang Z, McCallum SA, Xie J, Nieto L, Corzana F, Jimenez-Barbero J, Chen M, Liu J, Linhardt RJ (2008) Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc 130:12998–13007
114. Zhang F, Yang B, Mellisa L, Kemal S, Xiao Z, Wang Z, Beaudet JM, Torelli AY, Dordick JS, Linhardt RJ (2011) Structural characterization of heparins from different commercial sources. Anal Bioanal Chem 401:2793–2803
115. Zhang C, Liu L, Teng L, Chen J, Liu J, Li J, Du G, Chen J (2012) Metabolic engineering of Escherichia coli BL21 for biosynthesis of heparosan, a bioengineered heparin precursor. Metab Eng 14:521–527. doi:10.1016/j.ymben.2012.06.005
116. Zhang J, Suflita M, Fiaschetti CM, Li G, Li L, Zhang F, Dordick JS, Linhardt RJ (2015a) High cell density cultivation of a recombinant Escherichia coli strain expressing a 6-O-sulfotransferase for the production of bioengineered heparin. J Appl Microbiol 118:92–98. doi:10.1111/jam.12684
117. Zhang J, Suflita M, Li G, Zhong W, Li L, Dordick JS, Linhardt RJ, Zhang F (2015b) High cell density cultivation of recombinant Escherichia coli strains expressing 2-O-sulfotransferase and C5-epimerase for the production of bioengineered heparin. Appl Biochem Biotechnol 175:2986–2995. doi:10.1007/s12010-014-1466-1
118. Zhou YJ, Hao XF, Tian ZJ, Tong GZ, Yoo D, An TQ, Zhou T, Li GX, Qiu HJ, Wei TC, Yuan XF (2008) Highly virulent porcine reproductive and respiratory syndrome virus emerged in China. Transbound Emerg Dis 55:152–164. doi:10.1111/j.1865-1682.2008.01020.x
119. Zhou X, Chandarajoti K, Pham TQ, Liu R, Liu J (2011) Expression of heparan sulfate sulfotransferases in Kluyveromyces lactis and preparation of 3′-phosphoadenosine-5′-phosphosulfate. Glycobiology 21:771–780. doi:10.1093/glycob/cwr001
120. Zoppetti G, Oreste P (2004) process for the preparation of chondroitin sulfates from K4 polysaccharide and obtained products. US Patent 6777398 B2